Skip to main content

Table 1 Baseline characteristics of the patients

From: Comparative impact of antiretroviral drugs on markers of inflammation and immune activation during the first two years of effective therapy for HIV-1 infection: an observational study

N (%) or median (interquartile range)
  Total n = 78 TDF/FTC n = 61 ABC/3TC n = 17 EFV n = 36 ATV/r n = 27 LPV/r n = 15
Sex: Male 71 (91%) 56 (91%) 15 (88%) 34 (94%) 22 (81%) 15 (100%)
Age, years 43 (34-47) 44 (35-49) 38 (32-43) 42 (34-46) 44 (35-48) 42 (33-55)
Body mass index 23 (22-24) 23 (22-25) 22 (21-24) 23 (22-25) 22 (21-25) 22 (21-24)
Current smokers 28 (36%) 25 (41%) 3 (18%) 14 (39%) 6 (22%) 8 (53%)
Viral hepatitis coinfection 6 (8%) 5 (8%) 1 (6%) 0 0 6 (40%)
Prior AIDS 7 (9%) 5 (8%) 2 (12%) 2 (6%) 1 (4%) 4 (27%)
CD4/mm 3 315 (217-409) 304 (190-384) 431 (330-512) 342 (262-402) 330 (263-446) 177 (72-299)
CD8/mm 3 959 (660-1345) 949 (656-1335) 1053 (762-1468) 981 (774-1240) 1111 (646-1506) 709 (454-1109)
CD4/CD8 ratio 0.30 (0.19-0.46) 0.28 (0.17-0.41) 0.49 (0.22-0.59) 0.33 (0.19-0.46) 0.29 (0.24-0.49) 0.16 (0.13-0.38)
Viral load (log 10 copies/mL) 4.6 (4.1-5.2) 4.7 (4.3-5.2) 4.4 (3.6-4.9) 4.8 (4.3-5.2) 4.4 (4-4.9) 5.1 (4.6-5.3)
Viral load > 5 log 10 36%      
  1. TDF, tenofovir; FTC, emtricitabine; ABC, abacavir; 3TC, lamivudine; EFV, efavirenz; ATV/r, atazanavir/ritonavir; LPV/r, lopinavir/ritonavir.
\